Europe has approximately 57 million adults living with diabetes, and this number is expected to reach 75 million by 2026, which would represent around 10% of the total population of Europe
Its preservative effect allows multiple withdrawals from the same vial, distinguishing it from sterile water for injection, which lacks preservatives and is intended for single use
The best candidates are patients who want to recover intelligently
INSTRUCTIONS FOR USE TRESIBA (tre-SI-bah) (insulin degludec) injection, for subcutaneous use FlexTouch Pen 100 units/mL Please read the following instructions carefully before using your TRESIBA FlexTouch Pen
Clicking the link below will connect you to begin the credit-claiming process for CME and MOC
(42) Long-Term Outcomes of Semaglutide Summary of Recent Trial Results SELECT Trial (2.4 mg): Demonstrated 20% MACE reduction in patients without diabetes, highlighting its effect beyond glycemic control